Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The intercellular cement and corneodesmosomes of the stratum corneum (SC) constitute the primary physical and permeability barrier of the human skin. The intercellular cement is a complex lipid matrix composed of ceramides, cholesterol, and free fatty acids organized into lamellar bilayers, which are essential for preventing transepidermal water loss (TEWL) and protecting against environmental pathogens (StatPearls, 2023). Corneodesmosomes are specialized cell-to-cell junctions that provide mechanical adhesion between corneocytes; they are composed of proteins such as corneodesmosin (CDSN), desmoglein 1 (DSG1), and desmocollin 1 (DSC1) (Haftek, 2003). In healthy skin, the process of desquamation is regulated by the enzymatic degradation of these corneodesmosomes by proteases, primarily kallikrein-related peptidases (KLKs), allowing for the orderly shedding of the outermost skin cells (Ishida-Yamamoto & Igawa, 2015). Dysregulation of these components is a hallmark of various dermatological diseases, including atopic dermatitis, where lipid deficiencies lead to barrier breakdown, and ichthyosis, where impaired desquamation results in scale accumulation (PubMed, 2018). Pharmacological interventions target these structures through the use of keratolytic agents (e.g., urea, salicylic acid) to promote desquamation or barrier-repair emollients (e.g., ceramide-containing topicals) to restore the lipid matrix (Del Rosso & Levin, 2011).
Keratolytic agents facilitate the degradation of corneodesmosomal proteins to promote desquamation, while lipid-based topicals replenish the intercellular cement to restore barrier integrity and reduce transepidermal water loss.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corneodesmosome and Intercellular Lipid Matrix of the Stratum Corneum (SC-CM/CD).